Response

Regina Kunz; Alex C. Spyropoulos; Frederick A. Spencer; Michael Mayr; Amir K. Jaffer; Mark H. Eckman; Andrew S. Dunn; James D. Douketis

doi:10.1378/chest.13-1728

Response

Regina Kunz
, Alex C. Spyropoulos
, Frederick A. Spencer
, Michael Mayr
, Amir K. Jaffer
, Mark H. Eckman
, Andrew S. Dunn
, James D. Douketis

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English
Pages (from-to)	1424-1426
Number of pages	3
Journal	Chest
Volume	144
Issue number	4
DOIs	https://doi.org/10.1378/chest.13-1728
State	Published - Oct 2013

Access to Document

10.1378/chest.13-1728

Cite this

@article{7f3a285ef4944dfaa48bc4a6185e0415,

title = "Response",

author = "Regina Kunz and Spyropoulos, \{Alex C.\} and Spencer, \{Frederick A.\} and Michael Mayr and Jaffer, \{Amir K.\} and Eckman, \{Mark H.\} and Dunn, \{Andrew S.\} and Douketis, \{James D.\}",

note = "Funding Information: Financial/nonfinancial disclosures: The authors of this guideline provided detailed conflict of interest information related to each individual recommendation made in this article. A grid of these disclosures is available online at http://chestjournal.chestpubs.org/content/141/2\_suppl/e326S/suppl/DC1 . In summary, the authors have reported to CHEST the following conflicts of interest: Dr Douketis was a consultant for Boerhinger-Ingelheim and served as a consultant during four advisory board meetings (by Sanofi-Aventis, Astra-Zeneca, Boehringer-Ingelheim, Pfizer) relating to the development and clinical use of novel, but not approved for clinical use, antiplatelet drugs (ticagrelor) and anticoagulant drugs (apixaban, semuloparin, dabigatran). Dr Eckman has received the following university grants: “Using Decision Analytic Modeling to Guide the ACCP Guideline Development Process for Antithrombotic Therapy in Atrial Fibrillation” (Foundation for Informed Medical Decision Making; October 2011-September 2013; \$185,000); “Cost-Effectiveness of Screening for Chronic Hepatitis C Infection” (Merck/Schering-Plough; October 2011-September 2012; \$58,000); “Greater Cincinnati BEACON Collaborative” (Office of the National Coordinator for Health Information Technology [90BC0016/01]; September 2010-March 2012; ∼ 15\% effort); “Cincinnati Center for Clinical and Translational Science and Training (CTSA) ARRA Supplement for Development of Distance Learning Program in Medical Informatics” (National Institutes of Health [NIH]/National Center for Research Resources [NCRR] [UL1 RR026314-01S1]; August 2009-August 2011; ∼ 20\% effort); “Cincinnati Center for Clinical and Translational Science and Training (CTSA)” (NIH/NCRR [1U54 RR 025216]; January 2009-February 2014; ∼ 15\% effort); “A Patient Specific Decision Support Tool for Bariatric Surgery” (National Institute of Diabetes and Digestive and Kidney Diseases [K23 DK075599]; August 2007-June 2012; no financial support); National Heart, Lung, and Blood Institute (K23 HL085387; June 2008-March 2013; no financial support); and “Cost-Effectiveness of Screening for Chronic Hepatitis B Infection” (Gilead Sciences Inc; March 2008-August 2010; ∼ \$56,000). He has also served as consultant for Savient Pharmaceuticals (“Cost Effectiveness Analysis of Gout Medication”; 2010; ∼ \$300) and as editorial consultant for the ACP (“Physicians' Information and Education Resource [PIER]: Module on Pre-Operative Assessment for Bleeding Disorders”; 2006-present; ∼ \$250/year). Dr Spyropoulos has served as a consultant to Pfizer, Sanofi-Aventis, and EISAI. Dr Jaffer served as a consultant to sanofi-aventis, Janssen, Canyon Pharmaceuticals, Boehringer Ingelheim, and Daiichi Sankyo; he has formerly spoken on behalf of sanofi-aventis. Dr Jaffer is also on the steering committee of an NHLBI clinical trial. Dr Kunz is a member of the GRADE Working Group, the methodology of which is used in these guidelines. She has an interest in seeing this methodology applied. Drs Spencer, Mayr, and Dunn have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. ",

year = "2013",

month = oct,

doi = "10.1378/chest.13-1728",

language = "English",

volume = "144",

pages = "1424--1426",

journal = "Chest",

issn = "0012-3692",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Response

AU - Kunz, Regina

AU - Spyropoulos, Alex C.

AU - Spencer, Frederick A.

AU - Mayr, Michael

AU - Jaffer, Amir K.

AU - Eckman, Mark H.

AU - Dunn, Andrew S.

AU - Douketis, James D.

N1 - Funding Information: Financial/nonfinancial disclosures: The authors of this guideline provided detailed conflict of interest information related to each individual recommendation made in this article. A grid of these disclosures is available online at http://chestjournal.chestpubs.org/content/141/2_suppl/e326S/suppl/DC1 . In summary, the authors have reported to CHEST the following conflicts of interest: Dr Douketis was a consultant for Boerhinger-Ingelheim and served as a consultant during four advisory board meetings (by Sanofi-Aventis, Astra-Zeneca, Boehringer-Ingelheim, Pfizer) relating to the development and clinical use of novel, but not approved for clinical use, antiplatelet drugs (ticagrelor) and anticoagulant drugs (apixaban, semuloparin, dabigatran). Dr Eckman has received the following university grants: “Using Decision Analytic Modeling to Guide the ACCP Guideline Development Process for Antithrombotic Therapy in Atrial Fibrillation” (Foundation for Informed Medical Decision Making; October 2011-September 2013; $185,000); “Cost-Effectiveness of Screening for Chronic Hepatitis C Infection” (Merck/Schering-Plough; October 2011-September 2012; $58,000); “Greater Cincinnati BEACON Collaborative” (Office of the National Coordinator for Health Information Technology [90BC0016/01]; September 2010-March 2012; ∼ 15% effort); “Cincinnati Center for Clinical and Translational Science and Training (CTSA) ARRA Supplement for Development of Distance Learning Program in Medical Informatics” (National Institutes of Health [NIH]/National Center for Research Resources [NCRR] [UL1 RR026314-01S1]; August 2009-August 2011; ∼ 20% effort); “Cincinnati Center for Clinical and Translational Science and Training (CTSA)” (NIH/NCRR [1U54 RR 025216]; January 2009-February 2014; ∼ 15% effort); “A Patient Specific Decision Support Tool for Bariatric Surgery” (National Institute of Diabetes and Digestive and Kidney Diseases [K23 DK075599]; August 2007-June 2012; no financial support); National Heart, Lung, and Blood Institute (K23 HL085387; June 2008-March 2013; no financial support); and “Cost-Effectiveness of Screening for Chronic Hepatitis B Infection” (Gilead Sciences Inc; March 2008-August 2010; ∼ $56,000). He has also served as consultant for Savient Pharmaceuticals (“Cost Effectiveness Analysis of Gout Medication”; 2010; ∼ $300) and as editorial consultant for the ACP (“Physicians' Information and Education Resource [PIER]: Module on Pre-Operative Assessment for Bleeding Disorders”; 2006-present; ∼ $250/year). Dr Spyropoulos has served as a consultant to Pfizer, Sanofi-Aventis, and EISAI. Dr Jaffer served as a consultant to sanofi-aventis, Janssen, Canyon Pharmaceuticals, Boehringer Ingelheim, and Daiichi Sankyo; he has formerly spoken on behalf of sanofi-aventis. Dr Jaffer is also on the steering committee of an NHLBI clinical trial. Dr Kunz is a member of the GRADE Working Group, the methodology of which is used in these guidelines. She has an interest in seeing this methodology applied. Drs Spencer, Mayr, and Dunn have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

PY - 2013/10

Y1 - 2013/10

UR - https://www.scopus.com/pages/publications/84885124205

U2 - 10.1378/chest.13-1728

DO - 10.1378/chest.13-1728

M3 - Letter

C2 - 24081368

AN - SCOPUS:84885124205

SN - 0012-3692

VL - 144

SP - 1424

EP - 1426

JO - Chest

JF - Chest

IS - 4

ER -